

Concentrated and Active

High conviction global equity portfolio

Companies with an Economic Franchise

Large economic moats with a history of stable forecastable earnings

Strict Valuation Discipline

Benefits of Economic Franchises at a Discount to Intrinsic Value

Fund Facts

Number of stocks	29
Total Fund Size	\$125m
Inception Date	1 October 2013
Total Management Costs	1.25% p.a.
Index	MSCI World
Minimum Investment	\$20,000
Buy/Sell Spread	+0.20%/-0.20%
Distributions	Annually
APIR Code	LAZ0025AU


Investment Characteristics

	Lazard	Index
Forward Price/Earnings	16.8	21.0
Forward Return on Equity (%)	15.4	13.9
Sharpe Ratio (Since Inception)	1.0	1.1
Dividend Yield (%)	2.4	1.7
Active Share (%)	98.0	-

Performance (%)

	Lazard	Index	Excess Return
1 Month	3.3	3.2	0.2
3 Months	12.5	10.2	2.3
1 Year	28.4	23.2	5.2
3 Years (pa)	7.8	13.2	-5.4
5 Years (pa)	11.6	13.8	-2.1
Since Inception (pa)	14.1	13.7	0.4

Growth of \$20,000



Investments can go up and down. Past performance is not necessarily indicative of future performance. Fund returns are quoted after the deduction of Management Costs. Performance assumes reinvestment of all distributions.


Allocations (%)

Sector	Lazard	Index	Overweight/ Underweight
Consumer Staples	3.2	7.1	-3.9
Financials	0.0	13.8	-13.8
Communication Services	9.1	9.2	-0.2
Energy	0.0	3.0	-3.0
Real Estate	0.0	2.7	-2.7
Materials	0.0	4.6	-4.6
Health Care	26.5	12.3	14.2
Industrials	22.1	10.7	11.5
Information Technology	6.7	21.5	-14.8
Consumer Discretionary	13.8	12.1	1.6
Utilities	13.8	2.9	10.9
Cash	4.8	0.0	4.8
Region			
North America	49.6	70.2	-20.6
Continental Europe	34.4	14.7	19.7
United Kingdom	9.1	4.3	4.8
Asia Pacific ex-Japan	2.1	3.5	-1.5
Japan	0.0	7.1	-7.1
Middle East	0.0	0.2	-0.2
Cash	4.8	0.0	4.8

Top 5 Holdings (%)

	Lazard
CVS Health	6.0
H&R Block	6.0
Nielsen	6.0
Omnicom	5.6
Fresenius Medical Care	5.3

Investment Characteristics



Aa T 31 March 2021. Lazard estimates based on historical financial accounts of companies held in the Lazard Global Equity Franchise strategy. All estimates are based on current information and are subject to change.
Source: Lazard, Factset, MSCI

Commentary

Global equity markets continued their year-long rally into April 2021, rising over 3% in the month. Surging corporate profits, meaningful vaccine progress, and a continuation of the accommodative policies from the US Federal Reserve and European Central Bank provided ample support to sustain the rally. The United States led the major markets in the month, driven in part by a significant increase in company reported earnings in the quarter, which was well ahead of expectations. European markets were also comparatively strong as industrial figures showed a strong pick-up in new orders, overcoming another recession (as the eurozone reported two consecutive quarters of negative GDP growth).

The Lazard Global Equity Franchise Fund returned 3.34% (net of fees) during the month, outperforming the MSCI World Index which returned 3.19%.

Omnicom Group rose after delivering solid first quarter results, with margins above Q1 2020 levels and revenues better than expected. As a leading advertising and marketing services provider, Omnicom should be a clear beneficiary of the re-opening of developed economies in 2021. Apart from the Q1 result, CEO John Wren struck a confident tone, stating that he expects Omnicom's target of 'GDP plus' revenue growth to be achieved beyond any recovery from COVID-19. Given Omnicom has not achieved this target in years, we believe that such an outcome would likely lead to a material re-rating in the shares.

Dialysis provider Fresenius Medical Care performed well during the month as the market began to view the company's guidance of a 20% downturn in FY21 profit due to COVID-19 related mortality, as too conservative. Solid growth in Asia-Pacific, U.S. payor mix improvements and growth in products all should compensate for the mortality increases and the company's inexpensive valuation make it attractive.

Anheuser-Busch (AB) performed strongly in April 2021. AB is the world's largest brewer with approximately 25% market share and is one of the world's top consumer products companies, managing a portfolio of well over 200 beer brands and occupying the number one or two market position in 25 countries.

U.S. drug distributor McKesson performed poorly during the month on concerns that generic drug prices may be falling. The issue for McKesson is the spread rather than the absolute prices and it is unclear as yet where the greatest pressure will be felt. McKesson earns considerably higher margins on generics as distribution power is critical, in contrast with branded drugs where patent exclusivity means the manufacturer has the market power.

Terna fell marginally, as the market started to focus on the WACC reset for the 2022 tariff review. The regulator is expected to release indications in late 1H or early 2H 2021. We do not expect meaningful changes to the formula set up and regulatory consistency has been one of the major benefits of the Italian energy regulatory regime.

The Global Equity Franchise portfolio currently holds high-quality franchise companies with higher financial productivity than the market and that are trading at reasonable valuations. Our portfolio is now trading broadly in-line with intrinsic value but at a sizable discount to the broader MSCI World Index on a number of measures, most notably the EBIT multiple where the portfolio trades on a 20% discount. In spite of a sizable value discount, the financial productivity of the portfolio on a range of measure is a sizable premium to the MSCI World Index. We believe the economic franchise characteristics we seek for all our investments will continue to serve our investors well over the long run.

For more information, call us on 1800 825 287
or visit www.lazardassetmanagement.com.au

Disclaimer

The information in this Fact Sheet was prepared by Lazard Asset Management Pacific Co ABN 13 064 523 619, AFS License 238432, and should not be considered a recommendation to purchase, sell or hold any particular security. Securities and sectors mentioned in this Fact Sheet are presented to illustrate companies and sectors in which the Fund may invest. Holdings are subject to change daily. This Fact Sheet contains general information only and does not take account of your individual objectives, financial situation or needs. Investors should get professional advice as to whether an investment in the Fund is appropriate having regard to their particular investment needs, objectives and financial circumstances before investing. Investors should obtain a copy of the current PDS for the Fund, available at www.lazardassetmanagement.com.au or from your IDPS operator, and consider the PDS before making any decision about whether to acquire, or to continue to hold, the Fund. Neither Lazard nor any member of the Lazard Group, including Lazard Asset Management LLC and its affiliates guarantees in any way the performance of the Fund, repayment of capital from the Fund, any particular return from or any increase in the value of the Fund. An investment in the Fund does not represent deposits or other liabilities of any member of the Lazard Group.

Certain information included herein is derived by Lazard in part from an MSCI index or indices (the "Index Data"). However, MSCI has not reviewed this product or report, and does not endorse or express any opinion regarding this product or report or any analysis or other information contained herein or the author or source of any such information or analysis. Neither MSCI nor any third party involved in or related to the computing or compiling of the Index Data makes any express or implied warranties, representations, or guarantees concerning the Index Data or any information or data derived therefrom, and in no event will MSCI or any third party have any liability for any direct, indirect, special, punitive, consequential, or any other damages (including lost profits) relating to any use of this information. Any use of MSCI data requires a license from MSCI. None of the Index Data is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such.

As notified to unitholders in the 'Updated Information' page on our website, from the financial year commencing 1 July 2020, the Fund will operate as an attribution management investment trust (AMIT). Generally, it is expected that the tax position of unitholders will not substantially change as a result of the Fund becoming an AMIT. For the financial year commencing 1 July 2020, and for each financial year thereafter, instead of receiving an annual tax statement, unitholders will receive an AMIT Member Annual Statement (AMMA statement), and will be required to include information from the AMMA statement, including any income attributed to them, when preparing their tax return for that financial year and thereafter. To be clear, annual tax statements will be sent to unitholders for the financial year ended 30 June 2020. For further information please refer to our website: https://www.lazardassetmanagement.com/au/en_us/funds/updated-information. You can also contact our Client Services Team on 1800 825 287 or by email at investorqueries@lazard.com.